<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03231787</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-PLA-2016-86</org_study_id>
    <nct_id>NCT03231787</nct_id>
  </id_info>
  <brief_title>Clinical Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery</brief_title>
  <acronym>AFFEcT</acronym>
  <official_title>Randomized Parallel Multicenter Trial in Antiaggregated Patients With Proximal Femur Fracture Evaluating a Strategy to Shorten Time Until Surgery (AFFEcT Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Carlos III Health Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish Clinical Research Network - CAIBER</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      National, randomized, open, parallel, multicenter clinical trial of two comparison groups
      that will evaluate the feasibility of a strategy based on a diagnostic test to shorten the
      surgery time in antiaggregated patients with proximal femur fracture.

      The experimental group will undergo surgery as soon as platelet aggregability, according to
      the PLATELETWORKS® method is correct within 24-48 hours.

      The control group will undergo surgery according to the usual practice of the center taking
      into account the safety time of the antiplatelet agent.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2017</start_date>
  <completion_date type="Anticipated">December 17, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 17, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time from emergency admission to surgery</measure>
    <time_frame>Up to 120 hours</time_frame>
    <description>Time from emergency admission to surgery will be measured in hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Through hospitalization, an average of 5 days</time_frame>
    <description>Total blood loss calculated by Nadler's formula from date of surgery until date of discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for blood transfusion</measure>
    <time_frame>Through hospitalization, an average of 5 days</time_frame>
    <description>Need for blood transfusion during hospitalization and transfused units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preoperative hemoglobin</measure>
    <time_frame>12 hours before surgery</time_frame>
    <description>Measurement of preoperative hemoglobin during 12 h before surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative hemoglobin</measure>
    <time_frame>From 12 hours after surgery until date of discharge, an average of 5 days</time_frame>
    <description>Measurement of postoperative hemoglobin until discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical wound complications</measure>
    <time_frame>1 week and 30 days after surgery</time_frame>
    <description>It includes:
Wound infection
Wound dehiscence
Reoperation due to wound complications
Postoperative pain
Safety: including the incidence of deep venous thrombosis during admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical complications</measure>
    <time_frame>1 week and 30 days after surgery</time_frame>
    <description>Myocardial infarction, stroke, pulmonary embolism, pneumonia / respiratory infections, urinary tract infections, sepsis, new onset pressure ulcers, acute renal failure, heart failure, delirium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Functionality</measure>
    <time_frame>From date of admission until the day before surgery, an average of 2 days</time_frame>
    <description>Measurement of platelet functionality with plateletworks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Preoperative, 5 days after surgery, and 1, 6 and 12 months after surgery</time_frame>
    <description>Quality of life measured by EQ-5D-5L questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to admission to patient movilization</measure>
    <time_frame>From date of admission until the date of first movilization, an average of 3 days</time_frame>
    <description>Time to admission to patient movilization measured in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All causes mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost effectiveness ratio</measure>
    <time_frame>1 year</time_frame>
    <description>Cost effectiveness ratio (Δ cost / Δ effectiveness)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">156</enrollment>
  <condition>Femur Fracture</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this group the platelet aggregability will be evaluated and if it is normal, the surgery will be performed within 24-48 hours.
If it is not normal, the evaluation of platelet aggregability will be repeated daily until the third day or until it is normalized if it is earlier.
If at the third day is not normalized, it will proceed as with the control group, which will take into account the safety time of the drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group will wait for the safety time of the drug according to the usual practice of the center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Platelet function assay</intervention_name>
    <description>Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.
It will be used to measure platelet function after withdrawal of the antiplatelet agent.
If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours.</description>
    <arm_group_label>Experimental group</arm_group_label>
    <other_name>Plateletworks®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients of both sexes

          -  Patients with a proximal femoral fracture requiring surgery

          -  Patients receiving antiplatelet agents at the time of admission to the emergency room:
             AAS&gt; 100 mg / d (Aspirin®), Trifusal&gt; 300 mg / d (Digren®; Edigen®), clopidogrel
             (Plavix®), prasugrel ®), ticagrelor (Brilique ®) and ticlopidine (Tiklid ®).

          -  Patients who give their signed consent

        Exclusion Criteria:

          -  Multiple fractures

          -  Pathological fractures

          -  Patients receiving vitamin K antagonist oral anticoagulants (warfarin and
             acenocoumarol) or new oral anticoagulants (apixaban, rivaroxaban and dabigatran) or
             who have acquired congenital or acquired coagulopathy

          -  Patients with AAS ≤100mg, trifusal ≤300mg

          -  Patients who do not give their informed consent or their legal guardian
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria J Martinez Zapata, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria J Martinez Zapata, MD, PhD</last_name>
    <phone>+34935537901</phone>
    <email>mmartinezz@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Althaia, Xarxa Assistencial Universitària de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca J Reguant, MD, PhD</last_name>
      <email>freguant@althaia.cat</email>
    </contact>
    <investigator>
      <last_name>Francesca Reguant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mireia Rodriguez, MD, PhD</last_name>
      <email>mrodriguezpr@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Mireia Rodriguez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domingo Blanco, MD, PhD</last_name>
      <email>15228dbv@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Domingo Blanco, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2017</study_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

